We use cookies to optimize our website and our services. For our policies, please visit our Privacy Policy. Cookie Policy Accept all Dismiss Preferences MOBIDIAG ENABLING FASTER, MORE ACCESSIBLE MOLECULAR DIAGNOSTICS Home Solutions Products News Literature Company Contact Log in Hologic closes acquisition of Mobidiag Mobidiag, A Hologic Company develops and provides molecular diagnostics for infectious diseases and antibiotic resistances. Our goal is to make in vitro diagnostics fast, accurate and accessible to improve quality and efficiency of healthcare systems, help prevent the spreading of antibiotic resistances and create new opportunities for implementing diagnostics in routine. At Mobidiag, we have harnessed our existing technologies and expertise to rapidly develop and supply molecular diagnostic tests for coronavirus . As a result, we offer a complete solution for COVID-19 infection (targeted and syndromic) suited for all laboratory needs and capacities. About Mobidiag Novodiag® is providing rapid and sensitive on-demand results. With its wide panel offer, the fully automated Novodiag platform is ideal for complementing high-throughput screening solutions for immediate detection of infectious diseases when time-to-result is critical. Watch Novodiag® in action! Amplidiag® is a family of diagnostic tests for high-volume screening of infectious diseases and antibiotic resistances. Take the Amplidiag amplification kits even further by automating the workflow from primary sample to final result with Amplidiag® Easy. Watch Amplidiag® Easy in action! Learn more... Learn more... In the News Tuomas Tenkanen on isojen kauppojen mies September 9, 2021 Tulevatko tässä Suomen seuraavat yksisarviset? – huippusijoittaja kertoo, mitkä yhtiöt voivat nousta... September 5, 2021 Methods for detection of Helicobacter pylori from stool sample: current options and developments - B... August 16, 2021 View All In the Media Latest News Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe October 05, 2021 Hologic closes acquisition of Mobidiag June 17, 2021 Mobidiag to Be Acquired by Hologic, Innovator in Women’s Health Diagnostic Testing, for Approximately €668 Million April 08, 2021 View All News Upcoming Events There are no upcoming events at this time. Careers At Mobidiag, we work in cross-functional projects to bring the most innovative molecular diagnostics for infectious diseases to the market. At the same time,, we constantly share our knowledge and learn from each other. We appreciate diversity and believe it should be at the heart of our teams. As a result, we aim at recruiting people from a wide variety of backgrounds and experiences. Overall, our employees are driven by hard work and an excellent team spirit. Are you ready to become a MOBILIEVER? Contact Tests and instruments from Mobidiag are available throughout Europe and the Middle East. If you are interested in learning more about the company and our products focusing on molecular diagnostics for infectious diseases, please contact us. We are here to support you in your everyday lab work! Careers Contact us Latest tweets from Mobidiag Mobidiag, A Hologic CompanyFollow Fast and reliable in vitro #diagnostics solutions for infectious diseases #infectiousdiseases #antibioticresistance #COVID19 Mobidiag, A Hologic Company@Mobidiag·21 Sep Thank you to everyone who has followed us. As part of our integration into Hologic, we will no longer be posting on this channel. To keep up-to-date with the next stage of our journey follow @Hologic2 Reply on Twitter 1440286921192718351 Retweet on Twitter 1440286921192718351 1 Like on Twitter 1440286921192718351 2 Twitter 1440286921192718351 Mobidiag, A Hologic Company@Mobidiag·17 Jun Heureux d'annoncer le rachat de Mobidiag par @Hologic, une entreprise médicale innovante et leader mondial dans le domaine de la santé des femmes. Ce rachat permettra un accès plus rapide à nos solutions à l'échelle mondiale. #diagnostic https://investors.hologic.com/press-releases/press-release-d... Reply on Twitter 1405525403335229458 Retweet on Twitter 1405525403335229458 2 Like on Twitter 1405525403335229458 3 Twitter 1405525403335229458 Load More... Follow us on social media and stay updated on the latest news on molecular diagnostics for infectious diseases! We are Mobidiag (HQ) Keilaranta 16 A FIN-02150 Espoo Finland +358 10 5050 770 sales@mobidiag.com Mobidiag France 172 rue de Charonne Le Dorian B2 75011 Paris France +33 1 55 25 17 00 adv@mobidiag.com Mobidiag UK Herschel House, 58 Herschel Street, Slough, Berkshire, SL1 1PG, UK +44 (0) 333 305 7506 sales@mobidiag.com Mobidiag Sweden +358 10 5050 770 sales@mobidiag.com Site map Home Solutions Respiratory Infections Gastrointestinal Infections Antimicrobial Resistance Management Healthcare Associated Infections Sepsis Products Coronavirus solutions Novodiag® Solution (CE-IVD) COVID-19 Novodiag COVID-19 Amplidiag COVID-19 C. difficile Bacterial GE+ CarbaR+ Stool Parasites Amplidiag® Solution (CE-IVD) COVID-19 H. pylori+ClariR Viral GE CarbaR+VRE CarbaR+MCR Stool Parasites Bacterial GE C. difficile+027 LifeSciences (RUO) S7 Fusion Polymerase Amplidiag® Multiplex PCR Master Mix Corporate News Corporate News Events Blog Company About Us Quality Management Team Investors Careers Literature Contact Contact Us Worldwide Distributors Cookie Policy (EU) Search Search for: Contact Us Full Name (required) Institution (required) Email (required) Phone Subject Message (required) HOME SOLUTIONS PRODUCTS CORPORATE NEWS COMPANY LITERATURE CONTACT CLIENT PORTAL COOKIE POLICY (EU) Linkedin Twitter Facebook Copyright © Mobidiag Ltd. All Rights Reserved. Mobidiag, Novodiag®, Amplidiag® and mNAT® are trademarks or registered trademarks of Mobidiag Oy. Other trademarks mentioned on this website are the property of their respective owners. No rights to use any trademarks or logos are granted. Learn more about our Privacy policy. Website crafted by Design Reform.